Daniel Brennan J.'s Insider Trades & SAST Disclosures
Daniel Brennan J.'s most recent trade in Boston Scientific Corp. was a trade of 67,333 Common Stock done at an average price of $105.2 . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Daniel Brennan J..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 105.24 per share. | 18 Feb 2025 | 67,333 | 225,808 (0%) | 0% | 105.2 | 7,086,111 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 18,533 | 37,067 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.55 per share. | 18 Feb 2025 | 18,533 | 251,151 (0%) | 0% | 24.5 | 454,985 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 16,865 | 0 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 18 Feb 2025 | 16,865 | 268,016 (0%) | 0% | 17.3 | 291,090 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 15,642 | 31,285 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.09 per share. | 18 Feb 2025 | 15,642 | 283,658 (0%) | 0% | 27.1 | 423,742 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 104.67 per share. | 18 Feb 2025 | 14,630 | 232,618 (0%) | 0% | 104.7 | 1,531,366 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 9,483 | 37,934 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 40.12 per share. | 18 Feb 2025 | 9,483 | 293,141 (0%) | 0% | 40.1 | 380,458 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 104.08 per share. | 18 Feb 2025 | 2,900 | 247,248 (0%) | 0% | 104.1 | 301,818 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 23,031 | 23,031 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 8,950 | 8,950 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,584 | 252,365 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,584 | 0 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,362 | 247,700 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,362 | 8,725 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,243 | 249,833 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,243 | 4,243 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 2,217 | 250,148 (0%) | 0% | 106.1 | 235,246 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 2,110 | 245,590 (0%) | 0% | 106.1 | 223,892 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 2,052 | 247,781 (0%) | 0% | 106.1 | 217,738 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 3,654 | 245,105 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 3,654 | 10,963 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.77 per share. | 12 Feb 2025 | 1,767 | 243,338 (0%) | 0% | 105.8 | 186,896 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 33,944 | 257,865 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.98 per share. | 11 Feb 2025 | 16,414 | 241,451 (0%) | 0% | 106.0 | 1,739,556 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 105.07 per share. | 11 Feb 2025 | 15,087 | 241,451 (0%) | 0% | 105.1 | 1,585,135 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 11 Feb 2025 | 15,087 | 256,538 (0%) | 0% | 16.3 | 246,069 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2025 | 15,087 | 0 | - | - | Stock Option (Right to Buy) | |
|
Waters Corp.
|
Daniel J. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 818 | 818 | - | - | Stock Option (Right to Buy) | |
|
Waters Corp.
|
Daniel J. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 319 | 1,025 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 14,901 | 238,822 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 14,901 | 0 | - | - | Performance Share Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 89.86 per share. | 01 Jan 2025 | 9,689 | 223,921 (0%) | 0% | 89.9 | 870,636 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 89.32 per share. | 01 Jan 2025 | 5,212 | 233,610 (0%) | 0% | 89.3 | 465,536 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 75.91 per share. | 22 May 2024 | 64,454 | 271,542 (0%) | 0% | 75.9 | 4,892,819 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 75.11 per share. | 22 May 2024 | 47,621 | 223,921 (0%) | 0% | 75.1 | 3,576,932 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.55 per share. | 22 May 2024 | 16,863 | 288,405 (0%) | 0% | 24.6 | 413,987 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 16,863 | 16,865 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 16,863 | 55,600 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 22 May 2024 | 16,863 | 305,268 (0%) | 0% | 17.3 | 291,055 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.09 per share. | 22 May 2024 | 15,642 | 320,910 (0%) | 0% | 27.1 | 423,742 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 15,642 | 46,927 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 22 May 2024 | 15,086 | 335,996 (0%) | 0% | 16.3 | 246,053 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 15,086 | 15,087 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel Brennan J. | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 13,662 | 0 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
J. Daniel Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 65.86 per share. | 16 Feb 2024 | 13,662 | 271,542 (0%) | 0% | 65.9 | 899,779 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.08 per share. | 16 Feb 2024 | 13,662 | 285,204 (0%) | 0% | 13.1 | 178,699 | Common Stock |
|
Boston Scientific Corp.
|
Brennan J. Daniel | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 4,583 | 271,513 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel Brennan J. | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 4,583 | 4,584 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel Brennan J. | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 4,243 | 268,812 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 4,243 | 8,486 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
J. Daniel Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 3,706 | 273,186 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel Brennan J. | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 3,706 | 0 | - | - | Deferred Stock Units | |
|
Boston Scientific Corp.
|
J. Brennan Daniel | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.82 per share. | 16 Feb 2024 | 2,033 | 269,480 (0%) | 0% | 65.8 | 133,812 | Common Stock |
|
Boston Scientific Corp.
|
Brennan J. Daniel | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.82 per share. | 16 Feb 2024 | 1,882 | 266,930 (0%) | 0% | 65.8 | 123,873 | Common Stock |
|
Boston Scientific Corp.
|
J. Brennan Daniel | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.82 per share. | 16 Feb 2024 | 1,644 | 271,542 (0%) | 0% | 65.8 | 108,208 | Common Stock |
|
Boston Scientific Corp.
|
J. Daniel Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 4,362 | 13,087 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
J. Daniel Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 4,362 | 266,504 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
J. Daniel Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.95 per share. | 14 Feb 2024 | 1,935 | 264,569 (0%) | 0% | 65.9 | 127,613 | Common Stock |
|
Boston Scientific Corp.
|
Brennan Daniel J. | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 38,537 | 38,537 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
J. Brennan Daniel | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 14,617 | 14,617 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
J. Brennan Daniel | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 36,666 | 278,404 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Brennan Daniel J. | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 06 Feb 2024 | 16,262 | 262,142 (0%) | 0% | 0 | Common Stock | |
|
Waters Corp.
|
Brennan Daniel J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 847 | 847 | - | - | Stock Option (Right to Buy) | |
|
Waters Corp.
|
J. Brennan Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 334 | 706 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
J. Brennan Daniel | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 23,979 | 249,937 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Brennan J. Daniel | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 23,979 | 0 | - | - | Performance Share Units | |
|
Boston Scientific Corp.
|
Brennan J. Daniel | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.81 per share. | 01 Jan 2024 | 8,199 | 241,738 (0%) | 0% | 57.8 | 473,984 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 46.64 per share. | 01 Mar 2023 | 75,610 | 255,958 (0%) | 0% | 46.6 | 3,526,337 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 46.66 per share. | 01 Mar 2023 | 30,000 | 225,958 (0%) | 0% | 46.7 | 1,399,914 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 01 Mar 2023 | 16,863 | 302,821 (0%) | 0% | 17.3 | 291,055 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 16,863 | 33,728 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 15,086 | 30,173 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 01 Mar 2023 | 15,086 | 317,907 (0%) | 0% | 16.3 | 246,053 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 13,661 | 13,662 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.08 per share. | 01 Mar 2023 | 13,661 | 331,568 (0%) | 0% | 13.1 | 178,686 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 3,661 | 0 | - | - | Deferred Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 3,661 | 287,582 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.23 per share. | 21 Feb 2023 | 1,624 | 285,958 (0%) | 0% | 46.2 | 75,078 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 4,583 | 283,892 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 4,583 | 9,167 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 4,243 | 280,559 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 4,243 | 12,729 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 3,706 | 285,565 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 3,706 | 3,706 | - | - | Deferred Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.54 per share. | 16 Feb 2023 | 2,033 | 281,859 (0%) | 0% | 46.5 | 94,616 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.54 per share. | 16 Feb 2023 | 1,644 | 283,921 (0%) | 0% | 46.5 | 76,512 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.48 per share. | 16 Feb 2023 | 1,250 | 279,309 (0%) | 0% | 46.5 | 58,100 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.39 per share. | 15 Feb 2023 | 7,572 | 280,954 (0%) | 0% | 7.4 | 55,957 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 7,572 | 0 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Sale of securities on an exchange or to another person at price $ 47.14 per share. | 15 Feb 2023 | 7,572 | 276,316 (0%) | 0% | 47.1 | 356,927 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 4,153 | 285,107 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 4,153 | 0 | - | - | Deferred Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.29 per share. | 15 Feb 2023 | 1,219 | 283,888 (0%) | 0% | 47.3 | 57,647 | Common Stock |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 45,404 | 45,404 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 17,449 | 17,449 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Daniel J. Brennan | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 14,901 | 14,901 | - | - | Performance Share Units | |
|
Waters Corp.
|
Daniel J. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 827 | 827 | - | - | Stock Option (Right to Buy) | |
|
Waters Corp.
|
Daniel J. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 318 | 372 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges